While the "superjab" represents a significant milestone for Moderna, the company remains focused on its continued pursuit of medical breakthroughs. It has already received priority review status from the Therapeutic Goods Administration in Australia for its RSV vaccine, a testament to Moderna's dedication to tackling respiratory illnesses head-on.